摘要
目的:研究罗格列酮对多种胰岛素抵抗(insulin resistance,IR)大鼠模型的作用。方法:分别建立2型糖尿病(T2DM)伴IR、高脂血症-IR、地塞米松(DX)诱导IR大鼠3种动物模型,观察罗格列酮对病鼠给药后2h血糖(FBG)、口服葡萄糖耐量试验(OGTT)后2h血糖(2hBG)以及给药后2h空腹血清血糖(FSG)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白-胆固醇(HDL-C)、低密度脂蛋白-胆固醇(LDL-C)、丙二醛(MDA),肿瘤坏死因子-α(TNF-α),胰岛素(Fins)含量及胰岛素敏感指数(ISI),超氧化物歧化酶(SOD)活性等指标的影响。结果:罗格列酮显著降低病鼠FSG,TC,TG,LDL-C和Fins、TNF-α的浓度(P<0.05),显著提高HDL-C含量及ISI(P<0.05),增强胰岛素敏感性。加强SOD活性和降低MDA的含量(P<0.05),增强抗氧化能力。结论:罗格列酮能调整各动物模型所致的糖脂代谢障碍,纠正高脂血症及高胰岛素血症,拮抗病鼠IR,改善其胰岛素敏感性,增强抗氧化作用。
OBJECTIVE To investigate the effects of roglitazone on insulin resistant rats induced by three series of different factors. METHODS Three animal models including type Ⅱ diabetic rats with insulin resistance (T2DR-IR) and dexamethasone-induced insulin resistant rats (DX-IR) and high fat and sugar diet-fed rats with hyperlipemia-insulin resistance were established performed, the effects of roglitazone on serum contents of fasting blood glucose(FBG), 2-hours blood glucose(2hBG) after oral glucose tolerance test(OGTT), the serum concentrations of fasting blood glucose (FSG), low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol (HDL-C), malondialdehyde (MDA), total cholesterols (TC), triacylglycerol (TG), leptin, tumor necrosis factor-α(TNF-α), fasting insulin (Fins) and index of insulin sensitivity (ISI), and activities of superoxide dismutase (SOD) were observed. RESULTS After administration of roglitazone, 2hBG after OGTT was significantly lowered (P〈0. (15) ; the IGT improved; the level of TG, TC, LDL-C were decreased (P〈0. 05) ; the content of HDL-C was heightened (P〈0. 05); the excessive contents of FSG, TNF-α and Fins were readjust (P〈0. (15), and enhanced ISI (P〈0. 0) ;the activity of SOD potentiated and content of MDA regressed (P〈0. 05). CONCLUSION Roglitazone can readjust hyperinsulinemia, correct hyperlipemia and hyperinsulinemia, enhance insulin sensitivity, antagonizing IR, and intensify antioxidation.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2007年第1期33-36,共4页
Chinese Journal of Hospital Pharmacy
基金
广东省中医药管理局(编号:101040
302002)
广州市医药卫生科技项目(编号:2004107)